evidence base comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
A study conducted by researchers at the University of Alabama examined the adhesive properties of fibrin tissue adhesives. The tests found that fibrin adhesives even at its intended medical concentration (29 mg/mL at the wound site) had shear strength of only 17.6 kiloPascals. Furthermore, another study performed at the University of California determined that the modulus (the stress/strain) of fibrin adhesives was on average 53.56 kPA. To seal together tissues the human body uses collagen and elastin to obtain superior shear strength. Type I collagen which includes collagen strands bundled into strong fibrils has a unique tri-helical structure which increases the proteins structural integrity. In fact, a study performed by the Department of Medicine in University College London experimentally determined that pure type I collagen has a modulus of 5 GPa to 11.5 GPa. Therefore, pure type I collagen has nearly one million times greater structural integrity than fibrin. Collagen is therefore much harder to deform than fibrin, and collagen fibers create much stronger bonds between tissues than strands of fibrin polymer.
=== Molecular target === Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of 1 mole docetaxel per mole tubulin in microtubules. This binding stabilizes microtubules and prevents depolymerisation from calcium ions, decreased temperature and dilution, preferentially at the plus end of the microtubule. Docetaxel has been found to accumulate to higher concentration in ovarian adenocarcinoma cells than kidney carcinoma cells, which may contribute to the more effective treatment of ovarian cancer by docetaxel. It has also been found to lead to the phosphorylation of oncoprotein bcl-2, which is apoptosis-blocking in its oncoprotein form.
When glutamic acid is dissolved in water, the amino group (−NH2) may gain a proton (H+), and/or the carboxyl groups may lose protons, depending on the acidity of the medium. In sufficiently acidic environments, both carboxyl groups are protonated and the molecule becomes a cation with a single positive charge, HOOC−CH(NH+3)−(CH2)2−COOH. At pH values between about 2.5 and 4.1, the carboxylic acid closer to the amine generally loses a proton, and the acid becomes the neutral zwitterion −OOC−CH(NH+3)−(CH2)2−COOH. This is also the form of the compound in the crystalline solid state. The change in protonation state is gradual; the two forms are in equal concentrations at pH 2.10. At even higher pH, the other carboxylic acid group loses its proton and the acid exists almost entirely as the glutamate anion −OOC−CH(NH+3)−(CH2)2−COO−, with a single negative charge overall. The change in protonation state occurs at pH 4.07. This form with both carboxylates lacking protons is dominant in the physiological pH range (7.35–7.45). At even higher pH, the amino group loses the extra proton, and the prevalent species is the doubly-negative anion −OOC−CH(NH2)−(CH2)2−COO−. The change in protonation state occurs at pH 9.47.
The Gulf War was notable for some of the first large-scale uses of precision-guided munitions, and stealth aircraft, via the Lockheed F-117 Nighthawk. Analysts refer to it as the "first space war" for the US usage of satellite-based reconnaissance, communications, and navigation. Precision-guided munitions, informally "smart bombs", were heralded as key in allowing military strikes to be made with a minimum of civilian casualties compared to previous wars, although they were not used as often as more traditional, less accurate bombs. Specific buildings in downtown Baghdad could be bombed while journalists in their hotels watched cruise missiles fly by. Precision-guided munitions amounted to approximately 7.4% of all bombs dropped by the coalition. Other bombs included cluster bombs, which disperse numerous submunitions, and daisy cutters, 15,000-pound bombs which can disintegrate everything within hundreds of yards. Global Positioning System (GPS) units were relatively new at the time and were important in enabling coalition units to easily navigate across the desert. Since military GPS receivers were not available for most troops, many used commercially available units. To permit these to be used to best effect, the "selective availability" feature of the GPS system was turned off for the duration of Desert Storm, allowing these commercial receivers to provide the same precision as the military equipment. Airborne Warning and Control System (AWACS) and satellite communication systems were also important.
Sources: en.wikipedia.org
A morgen ("morning" in Dutch and German) was approximately the amount of land tillable by one man behind an ox in the morning hours of a day. This was an official unit of measurement in South Africa until the 1970s, and was defined in November 2007 by the South African Law Society as having a conversion factor of 1 morgen = 0.856532 hectares. This unit of measure was also used in the Dutch colonial province of New Netherland (later New York and parts of New England).
Fluorotelomer-based products have been shown to degrade to PFOA over periods of decades; these studies could lead EPA to require DuPont and others to reformulate products with a value over $1 billion.
=== Chesapeake Bay restoration === Moore said he would support Chesapeake Bay restoration efforts by promoting "accountability and enforcement" in Maryland, as well as in neighboring states, use federal funds to upgrade water and wastewater systems, and by increasing the number of environmental inspectors. In October 2022, he told Lancaster Farming that he would develop a plan to accelerate projects to improve water quality and cut carbon emissions in his administration's first 100 days, and supported the restoration of the state's Chesapeake Bay Restoration Fund. In July 2023, Moore signed executive orders to refocus cleanup efforts onto shallow areas of the bay and to establish the Council on the Chesapeake and Coastal Bays to research state policy on oyster restoration and harvesting. From October 2023 to December 2025, Moore served as the chair of the Chesapeake Executive Council. During the 2025 legislative session, Moore introduced the Bay Legacy Act, which would promote regenerative farming practices on public lands, increase support for agricultural and oyster farmers, and improve the Maryland Department of Natural Resources's water quality monitoring methods. The Bay Legacy Act passed and was signed into law by Moore in May 2025. In December 2025, Moore, Delaware Governor Matt Meyer, Virginia Governor Glenn Youngkin, and Pennsylvania Governor Josh Shapiro approved a new cleanup plan that extended the Chesapeake Bay restoration effort to 2040 and includes commitments to reducing sediment pollution to the Bay.
==== UPMC Passavant ==== UPMC Passavant is UPMC's tertiary care hospital of Pittsburgh's northern suburbs that consist of two campuses, one in McCandless and another in Cranberry Township with a combined 423 beds. Founded by Lutherans in 1849, Passavant was the first Protestant hospital built in the United States. In 1964, Passavant moved from the City of Pittsburgh to its location in McCandless to serve the communities of northern Allegheny and southern Butler counties. Passavant merged with UPMC in 1997 and in 2002, as part of UPMC's acquisition of St. Francis Medical Center for the conversion of its flagship facility into the new Children's Hospital of Pittsburgh, UPMC converted St. Francis' hospital in Cranberry into a satellite campus of UPMC Passavant. In 2010, a seven-story 188,000 square foot patient pavilion was opened on the McCandless campus bringing total beds there to 399.
This GHK-Cu enriched material stimulated wound contraction and cell proliferation, as well as increased expression of antioxidant enzymes. The same material was tested for wound healing in diabetic rats. GHK-Cu treatment resulted in faster wound contraction and epithelization, higher level of glutathione and ascorbic acid, increased synthesis of collagen, and activation of fibroblasts and mast cells. Ischemic open wounds in rats treated with GHK-copper healed faster and had decreased concentration of metalloproteinases 2 and 9 as well as of tumor necrosis factor-beta (a major inflammatory cytokine) compared with vehicle alone or with untreated wounds.
Sources: en.wikipedia.org
Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.
According to the latest official projection, Brazil's estimated population was 214,211,951 on 1 July 2026—an increase from the figure of 203 million reported by the 2022 census. The population of Brazil, as recorded by the 2008 PNAD, was approximately 190 million (22.31 inhabitants per square kilometer or 57.8/sq mi), with a ratio of men to women of 0.95:1 and 83.75% of the population defined as urban. The population is heavily concentrated in the Southeast (89 million inhabitants) and Northeast (54.6 million inhabitants), while the two most extensive regions, the Center-West and the North, which together make up 64.12% of Brazilian territory, have a total of only 33.8 million inhabitants. The first census in Brazil was carried out in 1872 and recorded a population of 9,930,478. From 1880 to 1930, four million Europeans arrived. Brazil's population increased significantly between 1940 and 1970, because of a decline in the mortality rate, even though the birth rate underwent a slight decline. In the 1940s the annual population growth rate was 2.4%, rising to 3.0% in the 1950s and remaining at 2.9% in the 1960s, as life expectancy rose from 44 to 54 years, and to 72.6 years in 2007. It has been steadily falling since the 1960s, from 3.04% per year between 1950 and 1960 to 1.05% in 2008 and is expected to fall to a negative value of –0.29% by 2050, thus completing the demographic transition. In 2022, the illiteracy rate was roughly 7%, a significant decline from 11.48% in 2008. By comparison, in 1940, more than half the population (54%) was illiterate.
== See also == International Journal of Pediatric Obesity Task Force on Childhood Obesity Classification of childhood obesity Obesity and the environment Social influences on fitness behavior Social stigma of obesity Sugary drink tax EPODE International Network Transport:
=== Reactive oxygen species generation === Alloxan (C4H2N2O4) readily undergoes redox cycling with its one-electron (C4H3N2O4• semiquinone) and two-electron (dialuric acid, C4H4N2O4) reduction products. In the presence of intracellular reductants such as glutathione (or other thiols), this leads to the generation of toxic reactive oxygen species (ROS) via the interaction of alloxan reduction products with molecular oxygen and related species:
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.